CEL-SCI reports 3rd consecutive month of record patient enrollment in 2015
CEL-SCI announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for itsinvestigational immunotherapy Multikine. 406 patients have been enrolled in the Phase III study to date. April 01, 2015